Gavin, have you heard of PV-267: a drug that targets proteins expressed by a group of genes called the Major Histocompatibility Complex?PV-267 , Timothy Coetzee says, is a protein-based drug that prevents the myelin fragments from binding to MHC. Are you and your team doing anything like this? This sounds like a very promising project.http://www.xconomy.com/new-york/2012/04/12/provid-pharma-leans-on-ms-societys-venture-fund-to-boost-lead-drug/
Your slides are great- but I found it impossible to watch the talk. Ok, I've got a slow internet connection so I'd go off and leave it to load, but then I discovered it would only load each section individually- took me nearly 2 hours to watch one presentation. Useless MS soc. IT again- why couldn't they use youtube
Re: " I found it impossible to watch the talk."I will ask the MS Society to load the video onto YouTube.
Re: "Gavin, have you heard of PV-267.."Yes, we have heard of it. It is still very early days. This drug has yet to reach phase 1.